Sarina Piha-Paul

Has grant

Associate Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sarina Piha-Paul is an Associate Professor at The University of Texas MD Anderson Cancer Center in the United States. Her research focuses on molecular characterization of various cancers, with significant contributions to the understanding of NUT carcinoma and advancements in therapeutic strategies for solid tumors. She has authored several recent articles that explore the efficacy and safety of novel cancer therapies, including various inhibitors and treatment combinations for advanced malignancies.

Recent Grants

Grant: Open

A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients with Cancer

Open Date: 2022-07-01

Close Date: 2029-07-01

Grant: Open

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of a Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likely to Express CSP

Open Date: 2022-06-01

Close Date: 2029-06-01

Grant: Open

A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics and Efficacy of CYC140, an Oral PLK1 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma

Open Date: 2022-03-01

Close Date: 2029-03-01

Grant: Open

A Phase I, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of PUR001 Administered Intravenously in Adult Patients with Advanced Solid Tumors

Open Date: 2022-03-01

Close Date: 2029-03-01

Grant: Open

A Phase 1 Open-Label, Dose-Escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients with Locally Advanced or Metastatic Solid Tumors

Open Date: 2021-08-01

Close Date: 2028-08-01

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (16)

Janos Roszik

The University of Texas MD Anderson Cancer Center

UNITED STATES

Sarina Piha-Paul

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry

Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia–Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors

Advancing Understanding and Therapeutic Strategies for NUT Sarcomas: Comprehensive Review of the Literature and Two Cases

A First-in-Human Study of cinrebafusp alfa, a HER2/4-1BB Bispecific Molecule, in Patients with HER2-Positive Advanced Solid Malignancies

A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors

A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors

First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors

Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma

Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Discordance of HER2 Expression and/or Amplification on Repeat Testing

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies

Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

A phase i study of ixazomib and erlotinib in patients with advanced solid tumors

Collaborators (16)

Janos Roszik

Kanwal Raghav

Stephen Liu

Bettzy Stephen

Andrew Bishop

Aung Naing

Apostolia M. Tsimberidou

Paula Pohlmann

Justin Moyers

Siqing Fu

David S. Hong

Funda Meric-Bernstam

VINOD RAVI

Mohamed Gouda

Kyaw Thein

Timothy Yap

Make your next move.